Biotech Stocks Reviews
- Will MDNA11 Cohort 3 Promising Biomarkers Translate to Responses?
Tue, May 3
Yesterday, Medicenna released additionaldatafor their IL-2 program MDNA11. The 3rdcohort (n=4) used a · more » - First Look At Genocea’s GEN-011 Data Underwhelms
Wed, Apr 13
Genocea (GNCA) reported underwhelming data at AACR for their targeted TIL approach, GEN-011. Remember, · more » - AFMD13+NK Data Continues Impressing at AACR22
Mon, Apr 11
Affimed MD Andersonreportedan update on their AFM13+NK cell program. The data was very promising and · more » - What Nektar’s IL-2 Flop Means For Space
Wed, Mar 16
Big news this week in bio land is that Nektar/Bristol Myers IL-2 drugfailedto benefit patients with · more » - Medicenna CSO Leaves In Midst of Ongoing Phase 1
Fri, Mar 4
Yesterday, Medicenna (MDNA)announceda clinical advisory board and strategic advisors. In the end of the · more » - 9Meters Delays SBS Data Yet Again
Wed, Mar 2
9 Meters Bio (NMTR) shared yesterday that their topline results for Phase 2 in Short Bowel Syndrome · more » - AFMD Prioritizing Combo Programs
Tue, Feb 22
The XBI biotech index was starting a see some consolidation during February in the low-mid $90s. · more » - How Bio Has Fared In Prior Rising Rate Environments
Sun, Jan 30
Last week, general and biotech-specific markets were attentive to macroeconomics the FED’s plans to · more » - Post JP Morgan ’22 Notes
Tue, Jan 18
The XBI has fallen below the $100 range, down 40% from peak a year ago. The largest healthcare · more »